Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Quarterly results
Director comp.
Acq. announced
Director departure
Appointed director
ORE PHARMACEUTICAL HOLDINGS INC. (ORXE) Create: Alert

All | News | Filings
Date FiledTypeDescription
07/22/2010 8-K Quarterly results
04/19/2010 8-K Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...
03/22/2010 8-K Form 8-K - Current report
02/12/2010 8-K Form 8-K - Current report
02/03/2010 8-K Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arran...
Docs: "ORE PHARMACEUTICAL HOLDINGS INC."
11/13/2009 8-K Form 8-K - Current report
10/21/2009 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modifications t...
Docs: "Amended and Restated Bylaws of Ore Pharmaceuticals Inc",
"Ore Pharmaceuticals Announces Shareholder Approval of All Annual Meeting Proposals and Reorganization into a Holding Company Structure"
09/10/2009 8-K Other Events, Financial Statements and Exhibits
Docs: "Copy of electronic slides to accompany presentations starting on or about September 11, 2009"
09/09/2009 8-K Form 8-K - Current report
08/19/2009 8-K Form 8-K - Current report
08/19/2009 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Item 5.02. Departure of Directors"
08/17/2009 8-K Quarterly results
Docs: "Second Quarter 2009 Financial Results Reported"
08/06/2009 8-K Termination of a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointmen...
Docs: "15",
"James W. Fordyce Named to Ore Pharmaceuticals Board of Directors"
07/27/2009 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
07/21/2009 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Departure of Directors o...
Docs: "14",
"Benjamin L. Palleiko Named Chief Financial Officer of Ore Pharmaceuticals"
06/29/2009 8-K Form 8-K -- Current report
05/28/2009 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modifications t...
Docs: "Bylaws of Ore Pharmaceuticals Inc., as amended",
"Ore Pharmaceuticals Inc. Announces NASDAQ Deficiency Notice"
04/10/2009 8-K Form 8-K -- Current report
03/03/2009 8-K Form 8-K -- Current report
02/26/2009 8-K Quarterly results
Docs: "Strategic Re-alignment Continues - Fourth Quarter 2008 Financial Results Reported"
01/15/2009 8-K Form 8-K -- Current report
11/18/2008 8-K Form 8-K -- Current report
10/02/2008 8-K Form 8-K -- Current report
09/23/2008 8-K Entry into a Material Definitive Agreement, Departure of Directors or Principal Officers; Election of Directors; Appointment ...
Docs: "04",
"DioGenix Spins Off from Parent Company Nerveda Acquires and Will Finance the Development of Non-Invasive Molecular Diagnostics"
08/06/2008 8-K Temporary Suspension of Trading Under Registrant's Employee Benefit Plans, Financial Statements and Exhibits
Docs: "By-laws of Ore Pharmaceuticals Inc., as amended"
06/17/2008 8-K Cost Associated with Exit or Disposal Activities, Financial Statements and Exhibits
Docs: "Ore Pharmaceuticals Focuses Resources on Development of Repositioned Compounds Strategic Realignment Streamlines Operations, Reduces Workforce"
06/12/2008 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and...
Docs: "Ore Pharmaceuticals Regains Compliance with NASDAQ Listing Requirements"
05/28/2008 8-K Other Events, Financial Statements and Exhibits
Docs: "Ore Pharmaceuticals Shareholders Approve One-for-Five Reverse Stock Split, Re-Election of Two Directors Reverse stock split to be effective at 5:00 PM Eastern Time"
04/30/2008 8-K Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers, Financial Statements ...
Docs: "3D"
03/27/2008 8-K Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers, Financial Statements ...
Docs: "2B"
03/14/2008 8-K Resignation/termination of a director
Docs: "Stock Purchase Agreement, by and among Lloyd I. Miller, III, Millfam II L.P., and Ore Pharmaceuticals Inc",
"Letter of Resignation from Lloyd I. Miller, III"
02/29/2008 8-K Asset disposition, Quarterly results
Docs: "Ore Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results Drug Repositioning and Development Now Company Focus"
12/20/2007 8-K Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits
Docs: "By-laws of Gene Logic Inc., as amended",
"Gene Logic Inc. Completes Sale of Genomics Assets to Ocimum Biosolutions Gene Logic Inc. Renamed Ore Pharmaceuticals Inc., Commitment to Drug Repositioning and Development Business Reaffirmed",
"Unaudited pro forma consolidated condensed balance sheet as of September 30, 2007 and unaudited pro forma consolidated condensed statements of operations for the nine months ended September 30, 2007 and for the three years ended December 31, 2006, including notes thereto"
12/20/2007 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and...
Docs: "Ore Pharmaceuticals Inc. Announces NASDAQ Deficiency Notice"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy